 SAN DIEGO--BUSINESS WIRE--Janux Therapeutics, Inc. Nasdaq: JANX Janux, a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager TRACTr and Tumor Activated Immunomodulator TRACIr platforms, today announced that Janux management will participate in three upcoming investor conferences: Cowens 42nd Annual Health Care Conference Forum: Panel titled Novel IO Location: Virtual Date: Monday 